SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending as community members discuss its potential within the decentralized storage sector and its competition with Amazon AWS. Speculation around AI and data infrastructure projects utilizing Filecoin's network is fueling interest, with some eyeing a return to all-time highs. Technical analysis and discussions of potential breakouts are also prominent.

Ethereum Classic

Ethereum Classic is trending as traders discuss its potential for a significant price increase, drawing comparisons to past bull runs and anticipating a move to catch up with Ethereum's recent gains. Community members are debating entry points and potential price targets, with some highlighting its proof-of-work mechanism and perceived undervaluation as bullish factors. The conversation also includes speculation about broader altcoin season dynamics and the potential impact of upcoming economic events.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending amid community excitement over its recent price surge and increased staking activity, with many drawing comparisons to ZCash's historical run. The discussion centers around ICP's unique technology, particularly its "full-stack on-chain" model and potential to disrupt traditional internet infrastructure, as well as speculation on short-term price targets.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as the community anticipates news, especially regarding potential pharmaceutical contracts and the closing of the pension transfer. Discussions center on Kodak's transformation beyond its legacy business, with optimism around its pharmaceutical and battery ventures. Some traders are looking at its potential as the next meme stock.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

MTSR is trending due to ongoing speculation around a potential buyout offer from pharmaceutical giants like $PFE and $NVO, driving community discussion about competing bids and the future of its obesity drug pipeline. The community is actively debating the potential value of MTSR's assets, with some believing the bidding war is far from over, while others suggest that potential regulatory hurdles or superior alternatives may shift focus elsewhere. Broader sector trends in weight-loss and metabolic disease treatments add further context.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending as investors eagerly await upcoming presentations at the AASLD Liver Meeting, sparking speculation about potential partnerships or a buyout. The community is focused on the potential of Belapectin, especially its synergistic effects when combined with GLP-1 drugs, in treating MASH cirrhosis. High short interest is fueling discussions of a possible short squeeze, with community members actively debating buyout price predictions and the potential for biomarker data to drive stock valuation.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai (FET) is trending amid discussions about its potential, partnerships, and the broader AI narrative in crypto, with some traders pointing to a possible breakout. Community members are weighing bullish prospects against concerns about its performance relative to other cryptocurrencies and speculating on potential catalysts. The conversation includes price predictions, comparisons to other AI coins, and mentions of upcoming news.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending as investors anticipate upcoming data presentations, particularly CTX310 at the American Heart Association meeting in November, which some believe could be a major catalyst. Bullish sentiment is fueled by insider buying and a growing consensus that the company is undervalued, with the potential for a significant short squeeze. Community members are closely watching for earnings and pipeline updates, while also speculating on potential acquisitions or partnerships.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASPI is trending as investors discuss the potential revenue boost from producing various isotopes, including those for next-generation SMR reactors. Community members are also excited about the momentum building with recycling tech, UK nuclear regulation progress, Trump family backing, and the upcoming investor event expected to provide more news to bolster the company valuation. The potential QLE spin-off continues to be a central point of discussion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors discuss the implications of Michael Weiss's recent stock transfer to family trusts, with some speculating it signals potential buyout negotiations. The community is also analyzing revenue growth and upcoming earnings, while also pointing to the potential impact of subq Briumvi and the company's long-term prospects within the competitive MS market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


lc88academy

LC88 Academy